{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:47:04Z","timestamp":1789199224192,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In neutropenic patients, bloodstream infections (BSI) significantly contribute to morbidity and mortality. Appropriate empirical antibiotic therapy (EAT) of BSI is essential, at the same time overconsumption of very broad-spectrum antibiotics should be avoided. We investigated: (1) whether surveillance cultures can predict BSI with third-generation cephalosporin \u2013resistant Enterobacterales and\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (3GC-R), (2) the effect of inappropriate empirical antimicrobial therapy (IEAT) on clinical outcome and (3) the potential reduction of carbapenem use when using surveillance cultures to guide therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of adult patients with haematological malignancies with febrile episodes during chemotherapy-induced high-risk neutropenia in whom surveillance cultures were collected weekly. IEAT was defined as the absence of in vitro susceptibility of blood-isolates to the administered EAT. Clinical outcome (ICU admission and death) was evaluated within 30\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 673 febrile episodes occurred among 372 high-risk neutropenic patients. BSI was present in 20.1% (135\/673), of which 25.9% (35\/135) were due to Enterobacterales and\n                      <jats:italic>P. aeruginosa.<\/jats:italic>\n                      Of these, 17\/35 were 3GC-R and 70.6% (12\/17) were preceded by 3GC-R colonization. Negative predictive value of surveillance cultures for 3GC-R BSI was 99.1%. IEAT due to (3GC-R) BSI was not significantly associated with clinical outcome. Using surveillance cultures to guide EAT could potentially reduce carbapenem use by 82.8%, when compared to standard EAT with carbapenem.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This retrospective analysis shows that in patients with high-risk neutropenia, surveillance cultures can potentially reduce the use of carbapenems with infrequent IEAT for 3GC-R BSI and no negative impact on clinical outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-022-01198-5","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:02:42Z","timestamp":1671321762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study"],"prefix":"10.1186","volume":"11","author":[{"given":"Jara R.","family":"de la Court","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarom","family":"Heijmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Sieswerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick A.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim C. E.","family":"Sigaloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier P.","family":"Schade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,18]]},"reference":[{"issue":"2","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00277-007-0390-7","volume":"87","author":"J Zuckermann","year":"2008","unstructured":"Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol. 2008;87(2):139\u201345. https:\/\/doi.org\/10.1007\/s00277-007-0390-7.","journal-title":"Ann Hematol"},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2334-14-13","volume":"14","author":"BG Bell","year":"2014","unstructured":"Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13. https:\/\/doi.org\/10.1186\/1471-2334-14-13.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"1198_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","volume":"177","author":"PD Tamma","year":"2017","unstructured":"Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177(9):1308\u201315. https:\/\/doi.org\/10.1001\/jamainternmed.2017.1938.","journal-title":"JAMA Intern Med"},{"key":"1198_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005197.pub3","volume":"11","author":"M Paul","year":"2010","unstructured":"Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;11: 005197. https:\/\/doi.org\/10.1002\/14651858.CD005197.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"1198_CR5","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","volume":"98","author":"D Averbuch","year":"2013","unstructured":"Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826\u201335. https:\/\/doi.org\/10.3324\/haematol.2013.091025.","journal-title":"Haematologica"},{"key":"1198_CR6","unstructured":"de la Court JR, de Jonge NA, Bomers M, et al. Empirische antibiotische therapie voor koorts bij neutropenie in Nederland. Ned Tijdschr Med Microbiol. 2018; 26(3)."},{"key":"1198_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00700-1","author":"JR de la Court","year":"2022","unstructured":"de la Court JR, Bruns AHW, Roukens AHE, et al. The Dutch Working Party on Antibiotic Policy (SWAB) recommendations for the diagnosis and management of febrile neutropenia in patients with cancer. Infect Dis Ther. 2022. https:\/\/doi.org\/10.1007\/s40121-022-00700-1.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1198_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12879-022-07154-3","volume":"22","author":"I Torres","year":"2022","unstructured":"Torres I, Huntly D, Tormo M, Calabuig M, Hern\u00e1ndez-Boluda JC, Terol JM, et al. Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. BMC Infect Dis. 2022;22(1):172. https:\/\/doi.org\/10.1186\/s12879-022-07154-3.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1198_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.jtct.2021.12.008","volume":"28","author":"D Dhanya","year":"2022","unstructured":"Dhanya D, Agarwal RK, Ramprakash S, Trivedi D, Shah V, Bhat N, et al. Do weekly surveillance cultures contribute to antibiotic stewardship and correlate with outcome of HSCT in children? A multicenter real-world experience of 5 years from the indian subcontinent. Transp Cell Ther. 2022;28(3):1701. https:\/\/doi.org\/10.1016\/j.jtct.2021.12.008.","journal-title":"Transp Cell Ther"},{"issue":"11","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s10096-018-3340-5","volume":"37","author":"N Tormo","year":"2018","unstructured":"Tormo N, Albert E, Borrajo E, Bosque M, Camarena JJ, Dom\u00ednguez V, et al. A survey on practices for active surveillance of carriage of multidrug-resistant bacteria in hospitals in the Autonomous Community of Valencia, Spain. Eur J Clin Microbiol Infect Dis. 2018;37(11):2069\u201374. https:\/\/doi.org\/10.1007\/s10096-018-3340-5. (Epub 2018 Aug 13 PMID: 30105621).","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1198_CR11","unstructured":"Centers for Disease Control and Prevention; National healthcare safety network, Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection) 2021; p. 4\u20138. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/4psc_clabscurrent.pdf"},{"key":"1198_CR12","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. The European Committee on Antimicrobial Susceptibility Testing. 2019. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf"},{"key":"1198_CR13","unstructured":"Bernards AT, Bonten MJM, Stuart CJ, Diederen BMW, Goessens WHF, Grundmann H, et al. Laboratory detection of highly resistant microorganisms (HRMO), version 2.0. Netherlands Society for Medical Microbiology Guideline 2017. https:\/\/www.nvmm.nl\/media\/1051\/2012_hrmo_mrsa_esbl.pdf"},{"key":"1198_CR14","unstructured":"EUCAST Expert Rules v 3.2 on Enterobacterales. 2019. https:\/\/kaldur.landspitali.is\/focal\/gaedahandbaekur\/gnhsykla.nsf\/5e27f2e5a88c898e00256500003c98c2\/5362662f687ffea60025805e00413b98\/$FILE\/Enterobacterales_ExpertRules_V3.2_20190613.pdf"},{"issue":"1","key":"1198_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1473-3099(16)30319-X","volume":"17","author":"MS Arcilla","year":"2017","unstructured":"Arcilla MS, van Hattem JM, Haverkate MR, Bootsma MJ, van Genderen PJJ, Goorhuis A, et al. Import and spread of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis. 2017;17(1):78\u201385. https:\/\/doi.org\/10.1016\/S1473-3099(16)30319-X.","journal-title":"Lancet Infect Dis"},{"issue":"6947","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/bmj.309.6947.102","volume":"309","author":"DG Altman","year":"1994","unstructured":"Altman DG, Bland JM. Statistics notes: diagnostic tests 2: predictive values. BMJ. 1994;309(6947):102. https:\/\/doi.org\/10.1136\/bmj.309.6947.102.","journal-title":"BMJ"},{"issue":"1","key":"1198_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00520-015-2772-z","volume":"24","author":"P Cornejo-Ju\u00e1rez","year":"2016","unstructured":"Cornejo-Ju\u00e1rez P, Su\u00e1rez-Cuenca JA, Volkow-Fern\u00e1ndez P, Silva-S\u00e1nchez J, Barrios-Camacho H, N\u00e1jera-Le\u00f3n E, et al. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer. 2016;24(1):253\u20139. https:\/\/doi.org\/10.1007\/s00520-015-2772-z.","journal-title":"Support Care Cancer"},{"issue":"7","key":"1198_CR18","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.bbmt.2018.02.021","volume":"24","author":"A Forcina","year":"2018","unstructured":"Forcina A, Lorentino F, Marasco V, Oltolini C, Marcatti M, Greco R, et al. Clinical impact of pretransplant multidrug-resistant gram-negative colonization in autologous and allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(7):1476\u201382. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.021.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1198_CR19","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/17474086.2020.1787145","volume":"13","author":"B K\u00f6m\u00fcrc\u00fc","year":"2020","unstructured":"K\u00f6m\u00fcrc\u00fc B, T\u00fckenmez Tigen E, Topta\u015f T, F\u0131ratl\u0131Tu\u011flular T, Korten V. Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study. Expert Rev Hematol. 2020;13:923\u20137. https:\/\/doi.org\/10.1080\/17474086.2020.1787145.","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s15010-012-0269-y","volume":"40","author":"BJ Liss","year":"2012","unstructured":"Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, F\u00e4tkenheuer G, Wisplinghoff H, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40(6):613\u20139. https:\/\/doi.org\/10.1007\/s15010-012-0269-y.","journal-title":"Infection"},{"issue":"1","key":"1198_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/tid.12323","volume":"17","author":"L Nesher","year":"2015","unstructured":"Nesher L, Rolston KV, Shah DP, Tarrand JT, Mulanovich V, Ariza-Heredia EJ, et al. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2015;17(1):33\u20138. https:\/\/doi.org\/10.1111\/tid.12323.","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"1198_CR22","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/cid\/ciy363","volume":"67","author":"MJ Satlin","year":"2018","unstructured":"Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, et al. Colonization with levofloxacin-resistant extended-spectrum \u03b2-lactamase-producing enterobacteriaceae and risk of bacteremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2018;67(11):1720\u20138. https:\/\/doi.org\/10.1093\/cid\/ciy363.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1198_CR23","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1093\/jac\/dku305","volume":"69","author":"MJ Vehreschild","year":"2014","unstructured":"Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, H\u00e4ntschel M, Peter S, et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. 2014;69(12):3387\u201392. https:\/\/doi.org\/10.1093\/jac\/dku305.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1198_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00277-007-0260-3","volume":"86","author":"H Narimatsu","year":"2007","unstructured":"Narimatsu H, Kami M, Miyakoshi S, Yuji K, Matusmura T, Uchida N, et al. Value of pretransplant screening for colonization of Pseudomonas aeruginosa in reduced-intensity umbilical cord blood transplantation for adult patients. Ann Hematol. 2007;86(6):449\u201351. https:\/\/doi.org\/10.1007\/s00277-007-0260-3.","journal-title":"Ann Hematol"},{"key":"1198_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/myc.13211","volume":"64","author":"CL Keighle","year":"2021","unstructured":"Keighle CL, Pope A, Marriott DJE, Chapman B, Bak N, Daveson K, et al. Risk factors for candidaemia: a prospective multi-centre case-control study. Mycoses. 2021;64:257\u201363. https:\/\/doi.org\/10.1111\/myc.13211.","journal-title":"Mycoses"},{"issue":"6","key":"1198_CR26","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/cid\/ciz319","volume":"70","author":"G Martinez-Nadal","year":"2020","unstructured":"Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A, Marco F, et al. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis. 2020;70(6):1068\u201374. https:\/\/doi.org\/10.1093\/cid\/ciz319.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1198_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cmi.2018.07.026","volume":"25","author":"P Puerta-Alcalde","year":"2019","unstructured":"Puerta-Alcalde P, Cardozo C, Su\u00e1rez-Lled\u00f3 M, Rodr\u00edguez-N\u00fa\u00f1ez O, Morata L, Feh\u00e9r C, et al. Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies. Clin Microbiol Infect. 2019;25(4):447\u201353. https:\/\/doi.org\/10.1016\/j.cmi.2018.07.026.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1198_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s15010-019-01370-x","volume":"48","author":"Y Tang","year":"2020","unstructured":"Tang Y, Wu X, Cheng Q, Li X. Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections. Infection. 2020;48(1):109\u201316. https:\/\/doi.org\/10.1007\/s15010-019-01370-x.","journal-title":"Infection"},{"issue":"3","key":"1198_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/qjmed\/hcg031","volume":"96","author":"F Vidal","year":"2003","unstructured":"Vidal F, Mensa J, Almela M, Olona M, Mart\u00ednez JA, Marco F, et al. Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosa. QJM. 2003;96(3):227\u201334. https:\/\/doi.org\/10.1093\/qjmed\/hcg031.","journal-title":"QJM"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-022-01198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-022-01198-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-022-01198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:02:57Z","timestamp":1671321777000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-022-01198-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1186\/s13756-022-01198-5","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,18]]},"assertion":[{"value":"16 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethic review board and the requirement to obtain informed consent was waived due to the retrospective nature of the study and the risk of selection bias due to the low 5-years survival in this patient population.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}